Oligonucleotides
Biotium CD43(SPN/1094), CF488A conjugate, 0.1mg/mL
This antibody recognizes a cell surface glycoprotein of 95/115/135 kDa (depending upon the extent of glycosylation), identified as CD43. 70-90% of T-cell lymphomas and from 22-37% of B-cell lymphomas express CD43. No reactivity has been observed with reactive B-cells. So a B-lineage population that co-expresses CD43 is highly likely to be a malignant lymphoma, especially a low-grade lymphoma, rather than a reactive B-cell population. When CD43 antibody is used in combination with anti-CD20, effective immunophenotyping of the lymphomas in formalin-fixed tissues can be obtained. Co-staining of a lymphoid infiltrate with anti-CD20 and anti-CD43 argues against a reactive process and favors a diagnosis of lymphoma.Primary antibodies are available purified, or with a selection of fluorescent CF Dyes and other labels. CF Dyes offer exceptional brightness and photostability. Note: Conjugates of blue fluorescent dyes like CF405S and CF405M are not recommended for detecting low abundan
Genscript Corporation CHO-K1/CRE-CBLuc/GLP1R
Recombinant CHO-K1 cells stably overexpress human glucagon like peptide 1 receptor (GLP1R) on the surface and contain high levels of G protein G s to couple with the receptor in downstream signaling pathways
LGC GENOMICS LLC (Lucigen) EpiScript™ RNase H- Reverse Transcriptase Kit, 200 U/L, 10,000 Units, 50 LAn optimised reverse transcriptase system for the production of full-length cDNA.
EpiScript™ Reverse Transcriptase an alternative to SuperScript II Reverse Transcriptase, is a recombinant MMLV reverse transcriptase with reduced RNase H activityProduce full-length cDNA with RNAse H-mutantAchieve higher specificity at elevated temperatures, up to 55 CKit Contents: EpiScript RNase H- Reverse Transcriptase, 10X Reaction Buffer, 100 mM DTT.
Biotium CD43(SPN/1094), 0.2mg/mL
This antibody recognizes a cell surface glycoprotein of 95/115/135 kDa (depending upon the extent of glycosylation), identified as CD43. 70-90% of T-cell lymphomas and from 22-37% of B-cell lymphomas express CD43. No reactivity has been observed with reactive B-cells. So a B-lineage population that co-expresses CD43 is highly likely to be a malignant lymphoma, especially a low-grade lymphoma, rather than a reactive B-cell population. When CD43 antibody is used in combination with anti-CD20, effective immunophenotyping of the lymphomas in formalin-fixed tissues can be obtained. Co-staining of a lymphoid infiltrate with anti-CD20 and anti-CD43 argues against a reactive process and favors a diagnosis of lymphoma.Primary antibodies are available purified, or with a selection of fluorescent CF Dyes and other labels. CF Dyes offer exceptional brightness and photostability. Note: Conjugates of blue fluorescent dyes like CF405S and CF405M are not recommended for detecting low abundan
ATCC HCM-BROD-0229-C25; Cancer Model Metastatic; Adenocarcinoma of pancreas; Human (Homo sapiens)
A patient-derived next-generation cancer model generated by the Human Cancer Models Initiative (HCMI). HCM-BROD-0229-C25 (ATCC No. PDM-168) was isolated from metastatic adenocarcinoma of pancreas tissue. This tumor-derived model can be used in basic research and pharmacological screening applications. Data for the tumor-derived organoid model is available at the GDC. Additional molecular characterizations may be available at the GDC. Additional controlled data may be available via dbGaP.